Obat Nyeri Sendi: Osteoarthritis Rheumatoid Arthritis Gout Arthritis

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 41

OBAT NYERI SENDI

OSTEOARTHRITIS
RHEUMATOID ARTHRITIS
GOUT ARTHRITIS
osteoarthritis
American College of Rheumatology2012
Recommendations
RHEMATOID ARTHRITIS
Joint Destruction

Modified from Immunex Corporation


Treatment Goals Treatment Approaches
• Relieve pain • Lifestyle modifications

• Reduce inflammation • Rest

• Prevent/slow joint damage • Physical and occupational


therapy
• Improve functioning and quality
of life • Medications

• Surgery
Traditional pyramid for treatment of RA

Assumptions:-
Exper 1) RA relatively benign disease
imental 2) NSAIDs less toxic than DMARDs
therapy
High dose
corticosteroids

Cyclophosphamide

Methotrexate, azathiaprine

Hydroxychloroquine Gold
Sulphasalazine salts

NSAIDs Low dose prednisone

Patient Physical Occupational High dose


education therapy therapy salicylates
Drug Treatments

• Nonsteroidal anti-inflammatory drugs (NSAIDs)

• Disease-modifying antirheumatic drugs (DMARDs)

• Biologic response modifiers

• Corticosteroids
Current therapies:
NSAIDs (COX2-inhibitor) & Corticosteroid
NSAID- anti-inflammatory & immunosuppressive effcts.
Corticosteroids are primarily used in short courses for flres or during the
initiation of DMARD therapy
(GI ulceration & Bleeding. Not DMARD)

Non-biological DMARDs
methotrexate, leflnomide, hydroxychloroquine, sulfasalazine, and
minocycline
→ relieving pain and inhibiting the progression of disease
Efficacy (refractory), Safety – Myelosuppression, Hepatic toxicity

Biological DMARDs
toclizumab, adalimumab, infliximab, golimumab and abatacept
→alter a specific step in the pathogenesis of the inflmmatory
response, eg TNF
more efficacy, lesser side effects, higher cost as compared to non-
biological DMARDs,
Safety – TB, Op infection, CHF, Demyelinating Disease, Lymphoma
NSAID dan
Kortikosteroid
Non Biological DMARDs

• FD : menekan
sistem kekebalan
tubuh memperlambat
laju kerusakan
jaringan &
progressifitas
penyakit.
Biological DMARDs
Promising Theraphy
Advantages of DMARDs

• Slow disease progression


• Improve functional disability
• Decrease pain
• Interfere with inflammatory processes
• Retard development of joint erosions
Selection of an Initial DMARD
Agent Time to benefit Potential Toxicities to monitor
Azathioprine 2-3 months toxicity
Moderate Myelosuppression,
hepatotoxicity,
Cyclosporin 4-8 weeks lymphoproliferative
Gold, oral 4-6 months High
Low Renal, hyperuricemia
Gold, parenteral 3-6 months
Moderate Myelosuppression, rash,
Hydroxychloroquine 2-4 months proteinuria,
Leflunomide 4-8 weeks gastrointestinal
Low Myelosuppression, rash
Methotrexate 1-3 months Low proteinuria
Macular damage
D-Penicillamine 3-6 months Moderate Hepatotoxicity,
gastrointestinal
Sulfasalazine 1-3 months Hepatotoxicity,
High pulmonary,
myelosuppression
GOUT ARTHRITIS
Tata Laksana
Hiperurosemia dan Gout
Target kerja Obat Anti-Hiperurisemia
URICOSURIC DRUG
Antiinflamasi pada Gout
Colchicine
MANAGEMENT OF ACUTE GOUT
MANAGEMENT OF PROPHYLAXIS GOUT

You might also like